SG11201803419PA - Methods of generating t-cells from stem cells and immunotherapeutic methods using the t-cells - Google Patents
Methods of generating t-cells from stem cells and immunotherapeutic methods using the t-cellsInfo
- Publication number
- SG11201803419PA SG11201803419PA SG11201803419PA SG11201803419PA SG11201803419PA SG 11201803419P A SG11201803419P A SG 11201803419PA SG 11201803419P A SG11201803419P A SG 11201803419PA SG 11201803419P A SG11201803419P A SG 11201803419PA SG 11201803419P A SG11201803419P A SG 11201803419PA
- Authority
- SG
- Singapore
- Prior art keywords
- cells
- methods
- generating
- immunotherapeutic
- stem
- Prior art date
Links
- 210000001744 T-lymphocyte Anatomy 0.000 title 2
- 230000001024 immunotherapeutic effect Effects 0.000 title 1
- 210000000130 stem cell Anatomy 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/463—Cellular immunotherapy characterised by recombinant expression
- A61K39/4631—Chimeric Antigen Receptors [CAR]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/463—Cellular immunotherapy characterised by recombinant expression
- A61K39/4632—T-cell receptors [TCR]; antibody T-cell receptor constructs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/7051—T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/0018—Culture media for cell or tissue culture
- C12N5/0037—Serum-free medium, which may still contain naturally-sourced components
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/0062—General methods for three-dimensional culture
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0603—Embryonic cells ; Embryoid bodies
- C12N5/0606—Pluripotent embryonic cells, e.g. embryonic stem cells [ES]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
- C12N5/0662—Stem cells
- C12N5/0663—Bone marrow mesenchymal stem cells (BM-MSC)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
- C12N5/0669—Bone marrow stromal cells; Whole bone marrow
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0696—Artificially induced pluripotent stem cells, e.g. iPS
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/05—Inorganic components
- C12N2500/10—Metals; Metal chelators
- C12N2500/20—Transition metals
- C12N2500/22—Zinc; Zn chelators
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/05—Inorganic components
- C12N2500/10—Metals; Metal chelators
- C12N2500/20—Transition metals
- C12N2500/24—Iron; Fe chelators; Transferrin
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/05—Inorganic components
- C12N2500/10—Metals; Metal chelators
- C12N2500/20—Transition metals
- C12N2500/24—Iron; Fe chelators; Transferrin
- C12N2500/25—Insulin-transferrin; Insulin-transferrin-selenium
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/30—Organic components
- C12N2500/32—Amino acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/30—Organic components
- C12N2500/38—Vitamins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/90—Serum-free medium, which may still contain naturally-sourced components
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/10—Growth factors
- C12N2501/125—Stem cell factor [SCF], c-kit ligand [KL]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/10—Growth factors
- C12N2501/145—Thrombopoietin [TPO]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/10—Growth factors
- C12N2501/15—Transforming growth factor beta (TGF-β)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/23—Interleukins [IL]
- C12N2501/2302—Interleukin-2 (IL-2)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/23—Interleukins [IL]
- C12N2501/2304—Interleukin-4 (IL-4)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/23—Interleukins [IL]
- C12N2501/2306—Interleukin-6 (IL-6)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/23—Interleukins [IL]
- C12N2501/2307—Interleukin-7 (IL-7)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/23—Interleukins [IL]
- C12N2501/2315—Interleukin-15 (IL-15)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/23—Interleukins [IL]
- C12N2501/2321—Interleukin-21 (IL-21)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/25—Tumour necrosing factors [TNF]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2513/00—3D culture
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- General Health & Medical Sciences (AREA)
- Cell Biology (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Developmental Biology & Embryology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Mycology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Rheumatology (AREA)
- Gynecology & Obstetrics (AREA)
- Reproductive Health (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Virology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Transplantation (AREA)
- Oncology (AREA)
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201562248931P | 2015-10-30 | 2015-10-30 | |
US201562265204P | 2015-12-09 | 2015-12-09 | |
US201662359456P | 2016-07-07 | 2016-07-07 | |
PCT/US2016/059375 WO2017075389A1 (en) | 2015-10-30 | 2016-10-28 | Methods of generating t-cells from stem cells and immunotherapeutic methods using the t-cells |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11201803419PA true SG11201803419PA (en) | 2018-05-30 |
Family
ID=58631163
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11201803419PA SG11201803419PA (en) | 2015-10-30 | 2016-10-28 | Methods of generating t-cells from stem cells and immunotherapeutic methods using the t-cells |
Country Status (13)
Country | Link |
---|---|
US (2) | US11154573B2 (en) |
EP (1) | EP3368660A4 (en) |
JP (2) | JP6983771B2 (en) |
KR (1) | KR20180092951A (en) |
CN (1) | CN108463548B (en) |
AU (2) | AU2016343682A1 (en) |
BR (1) | BR112018008648A2 (en) |
CA (1) | CA3003145A1 (en) |
IL (1) | IL258899B2 (en) |
MX (1) | MX2018005274A (en) |
SG (1) | SG11201803419PA (en) |
TW (2) | TWI812584B (en) |
WO (1) | WO2017075389A1 (en) |
Families Citing this family (66)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9719068B2 (en) | 2010-05-06 | 2017-08-01 | Children's Hospital Medical Center | Methods and systems for converting precursor cells into intestinal tissues through directed differentiation |
AU2015267148B2 (en) | 2014-05-28 | 2021-07-29 | Children's Hospital Medical Center | Methods and systems for converting precursor cells into gastric tissues through directed differentiation |
WO2016007570A2 (en) * | 2014-07-09 | 2016-01-14 | The Regents Of The University Of California | Engineered invariant natural killer t (inkt) cells and methods of making and using thereof |
CA2963704A1 (en) | 2014-10-17 | 2016-04-21 | Children's Hospital Medical Center | In vivo model of human small intestine using pluripotent stem cells and methods of making and using same |
MX2018005274A (en) * | 2015-10-30 | 2019-09-19 | The Regents Of The Universtiy Of California | Methods of generating t-cells from stem cells and immunotherapeutic methods using the t-cells. |
EP4177335A1 (en) | 2016-05-05 | 2023-05-10 | Children's Hospital Medical Center | Methods for the in vitro manufacture of gastric fundus tissue and compositions related to same |
CN110062764B (en) | 2016-12-05 | 2024-07-02 | 儿童医院医学中心 | Colonocytes and methods of making and using the same |
EP3555266B1 (en) * | 2016-12-13 | 2023-11-15 | The United States of America, as Represented by The Secretary, Department of Health and Human Services | Methods of preparing an isolated or purified population of thymic emigrant cells and methods of treatment using same |
CN110662831A (en) * | 2017-05-26 | 2020-01-07 | 凯德药业股份有限公司 | Methods of making and using embryonic mesenchymal progenitor cells |
EP3638262A4 (en) * | 2017-06-16 | 2021-03-24 | Mayo Foundation for Medical Education and Research | Materials and methods for increasing immune responses |
KR20200054178A (en) | 2017-08-09 | 2020-05-19 | 주노 쎄러퓨티크스 인코퍼레이티드 | Genetically engineered cell compositions and methods of making the related compositions |
KR101996218B1 (en) * | 2017-09-05 | 2019-10-01 | 주식회사 싸이토젠 | A method for screening cancer subjects based on axl |
US11898166B2 (en) | 2017-09-20 | 2024-02-13 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | In vitro generation of thymic organoid from human pluripotent stem cells |
JP2021509009A (en) * | 2017-11-30 | 2021-03-18 | ノバルティス アーゲー | BCMA Targeting Chimeric Antigen Receptor and Its Use |
MX2020005906A (en) * | 2017-12-08 | 2020-10-22 | Juno Therapeutics Inc | Phenotypic markers for cell therapy and related methods. |
EP3743510A1 (en) | 2018-01-28 | 2020-12-02 | Universite De Geneve | Arginase suppression for cancer treatment |
CA3090793A1 (en) | 2018-02-16 | 2019-08-22 | Kite Pharma, Inc. | Modified pluripotent stem cells and methods of making and use |
MX2020011023A (en) * | 2018-04-19 | 2021-01-29 | Baylor College Medicine | Reprogramming cd4 t cells into cytotoxic cd8 cells by forced expression of cd8ab and class 1 restricted t cell receptors. |
CN110499291B (en) * | 2018-05-16 | 2023-11-24 | 上海赛比曼生物科技有限公司 | Method for preparing chimeric antigen receptor T cells by serum-free culture |
CA3102801A1 (en) * | 2018-06-12 | 2019-12-19 | Lili Yang | Stem cell-engineered inkt cell-based off-the-shelf cellular therapy |
US11608382B2 (en) | 2018-06-13 | 2023-03-21 | Novartis Ag | BCMA chimeric antigen receptors and uses thereof |
US20210130777A1 (en) * | 2018-07-13 | 2021-05-06 | Kyoto University | Method for producing gamma delta t cells |
CA3110089A1 (en) * | 2018-08-28 | 2020-03-05 | Fred Hutchinson Cancer Research Center | Methods and compositions for adoptive t cell therapy incorporating induced notch signaling |
WO2020123015A1 (en) * | 2018-10-01 | 2020-06-18 | The Trustees Of Columbia University In The City Of New York | Three-dimensional co-culture system for high-throughput testing of therapeutics and diagnostics |
US20210355190A1 (en) * | 2018-10-31 | 2021-11-18 | Mayo Foundation For Medical Education And Research | Methods and materials for treating cancer |
CN109762843A (en) * | 2018-12-29 | 2019-05-17 | 武汉波睿达生物科技有限公司 | A method of general CAR-T cell is prepared using the CD3 positive T cell of derived from cord blood |
CN109652376B (en) * | 2019-01-08 | 2021-10-15 | 创芯国际生物科技(广州)有限公司 | Culture medium for 3D culture of ovarian cancer tissues |
CA3130442A1 (en) * | 2019-02-24 | 2020-08-27 | Gamida Cell Ltd. | Method of homing and retention of gammadelta t cells for generating cell compositions for use in therapy |
CN113767167A (en) * | 2019-04-26 | 2021-12-07 | 科罗拉多大学董事会,法人 | In vivo generation of functional and patient-specific thymus tissue from induced pluripotent stem cells |
US20210077536A1 (en) * | 2019-04-29 | 2021-03-18 | Biorestorative Therapies, Inc. | Non-naturally occuring three-dimensional (3d) brown adipose-derived stem cell aggregates, and methods of generating and using the same |
CN110106144B (en) * | 2019-05-17 | 2021-10-08 | 苏州大学 | Method and kit for inducing hematopoietic stem cells to differentiate into pre-T-lineage cells |
WO2020252303A1 (en) * | 2019-06-12 | 2020-12-17 | The Regents Of The University Of California | Engineered off-the-shelf immune cells and methods of use thereof |
WO2021006316A1 (en) * | 2019-07-10 | 2021-01-14 | 国立研究開発法人国立がん研究センター | Specific marker for identifying t cells specifically attacking cancer cells |
GB201911958D0 (en) * | 2019-08-20 | 2019-10-02 | Adaptimmune Ltd | Methods of t cell production |
CA3150095A1 (en) * | 2019-09-06 | 2021-03-11 | Shirley O'dea | Engineering of immune cells for ex vivo cell therapy applications |
CN112500492B (en) * | 2019-09-13 | 2023-08-04 | 中国科学院分子细胞科学卓越创新中心 | Chimeric antigen receptor and application thereof |
CN110499288A (en) * | 2019-09-17 | 2019-11-26 | 青岛华赛伯曼医学细胞生物有限公司 | The kit and its application that external evoked candidate stem cell breaks up to thymus T cells |
KR102081418B1 (en) * | 2019-09-24 | 2020-05-26 | 주식회사 이뮤니스바이오 | A medium composition of regulatory t cells derived from peripheral blood mononuclear cells and cultivation method using the same |
CN110872575A (en) * | 2019-10-21 | 2020-03-10 | 中冠赛尔生物科技(北京)有限公司 | In-vitro amplification method of iNKT cells |
AR120348A1 (en) * | 2019-11-01 | 2022-02-09 | Univ Kyoto | METHOD FOR PRODUCING T CELLS |
US20220362300A1 (en) * | 2019-11-05 | 2022-11-17 | City Of Hope | Generation of chimeric antigen receptor modified t cells from stem cells and therapeutic uses thereof |
EP4164706A1 (en) | 2019-12-04 | 2023-04-19 | Centre Hospitalier Universitaire Vaudois (CHUV) | Device and process for tissue-engineering and regenerative medicine |
GB202006903D0 (en) * | 2020-05-11 | 2020-06-24 | Adaptimmune Ltd | Modified iPSCs |
AU2021288213A1 (en) * | 2020-06-12 | 2023-02-02 | Adoc Ssf, Llc | Compositions and methods of manufacturing autologous T cell therapies |
CN111849913B (en) * | 2020-07-31 | 2021-05-25 | 南京北恒生物科技有限公司 | Engineered immune cells and uses thereof |
JP2023537526A (en) * | 2020-08-10 | 2023-09-01 | ヤンセン バイオテツク,インコーポレーテツド | Materials and methods for producing bioengineered virus-specific lymphocytes |
WO2022083667A1 (en) * | 2020-10-21 | 2022-04-28 | Nanjing Legend Biotech Co., Ltd. | Polypeptides comprising a vaccine specific tcr and a chimeric antigen receptor and uses thereof |
US20220211757A1 (en) * | 2020-12-28 | 2022-07-07 | The Regents Of The University Of California | Engineered gamma delta t cells and methods of making and using thereof |
WO2022235482A1 (en) * | 2021-05-03 | 2022-11-10 | Rutgers, The State University Of New Jersey | Immunotherapy for inflammatory bowel disease and/or cancer |
WO2022238890A1 (en) * | 2021-05-10 | 2022-11-17 | Bazaz Zohre | Method of producing antibodies from single plasma cells |
JP2024517968A (en) * | 2021-05-14 | 2024-04-23 | アピア バイオ, インコーポレイテッド | Production of engineered T cells from stem cells |
EP4347793A1 (en) * | 2021-05-25 | 2024-04-10 | Universiteit Gent | Generating t cell precursors via agonizing tumor necrosis factor receptor 2 |
CN117957313A (en) * | 2021-07-19 | 2024-04-30 | 修复免疫股份有限公司 | Method for producing immune cell population from pluripotent stem cells |
CN117836405A (en) * | 2021-08-13 | 2024-04-05 | 先声创新公司 | Three-dimensional culture of pluripotent stem cells to produce hematopoietic stem cells |
CA3234008A1 (en) * | 2021-09-27 | 2023-03-30 | Kyoto University | Method for producing t cell |
EP4416271A1 (en) * | 2021-10-14 | 2024-08-21 | Appia Bio, Inc. | Engineering stem cell t cells with multiple t cell receptors |
WO2023149555A1 (en) | 2022-02-04 | 2023-08-10 | 国立大学法人京都大学 | T cell production method |
CN114807031A (en) * | 2022-05-13 | 2022-07-29 | 山东赛恩福干细胞工程集团有限公司 | Construction method of human peripheral blood immune cell bank and stem cell bank |
CN115125203B (en) * | 2022-07-08 | 2023-10-27 | 珠海贝索细胞科学技术有限公司 | Th2 cell in-vitro culture method |
WO2024020365A1 (en) * | 2022-07-18 | 2024-01-25 | The Children's Medical Center Corporation | Methods of t cell differentiation and compositions thereof |
CN115181730B (en) * | 2022-07-29 | 2023-05-16 | 创芯国际生物科技(广州)有限公司 | Gastric stromal tumor organoid culture medium and culture method |
WO2024059733A2 (en) * | 2022-09-14 | 2024-03-21 | Fred Hutchinson Cancer Center | Chimeric antigen receptors binding nectin-4 |
WO2024091676A1 (en) * | 2022-10-28 | 2024-05-02 | The Regents Of The University Of Colorado, A Body Corporate | Compositions and methods for accelerated production of thymic cells from pluripotent stem cells |
WO2024111974A1 (en) * | 2022-11-23 | 2024-05-30 | 가톨릭대학교 산학협력단 | Method for mass production of immunosuppressive t cells using human serum albumin |
CN116622632A (en) * | 2023-05-29 | 2023-08-22 | 广州市妇女儿童医疗中心 | Application of CD4TEMRA in diagnosis of autism co-morbid epilepsy |
CN118406649B (en) * | 2024-07-02 | 2024-09-17 | 苏州依科赛生物科技股份有限公司 | CIK cell serum-free culture medium and application thereof |
Family Cites Families (103)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NL8200523A (en) | 1982-02-11 | 1983-09-01 | Univ Leiden | METHOD FOR TRANSFORMING IN VITRO PLANT PROTOPLASTS WITH PLASMIDE DNA. |
US4714680B1 (en) | 1984-02-06 | 1995-06-27 | Univ Johns Hopkins | Human stem cells |
US4683202A (en) | 1985-03-28 | 1987-07-28 | Cetus Corporation | Process for amplifying nucleic acid sequences |
US4952500A (en) | 1988-02-01 | 1990-08-28 | University Of Georgia Research Foundation, Inc. | Cloning systems for Rhodococcus and related bacteria |
US5703055A (en) | 1989-03-21 | 1997-12-30 | Wisconsin Alumni Research Foundation | Generation of antibodies through lipid mediated DNA delivery |
US5302523A (en) | 1989-06-21 | 1994-04-12 | Zeneca Limited | Transformation of plant cells |
US7705215B1 (en) | 1990-04-17 | 2010-04-27 | Dekalb Genetics Corporation | Methods and compositions for the production of stably transformed, fertile monocot plants and cells thereof |
US5550318A (en) | 1990-04-17 | 1996-08-27 | Dekalb Genetics Corporation | Methods and compositions for the production of stably transformed, fertile monocot plants and cells thereof |
US5322783A (en) | 1989-10-17 | 1994-06-21 | Pioneer Hi-Bred International, Inc. | Soybean transformation by microparticle bombardment |
US5484956A (en) | 1990-01-22 | 1996-01-16 | Dekalb Genetics Corporation | Fertile transgenic Zea mays plant comprising heterologous DNA encoding Bacillus thuringiensis endotoxin |
US5384253A (en) | 1990-12-28 | 1995-01-24 | Dekalb Genetics Corporation | Genetic transformation of maize cells by electroporation of cells pretreated with pectin degrading enzymes |
US5389640A (en) | 1991-03-01 | 1995-02-14 | Minnesota Mining And Manufacturing Company | 1-substituted, 2-substituted 1H-imidazo[4,5-c]quinolin-4-amines |
AU2515992A (en) | 1991-08-20 | 1993-03-16 | Genpharm International, Inc. | Gene targeting in animal cells using isogenic dna constructs |
EP0641781B1 (en) | 1991-09-06 | 2000-07-26 | Yoshitomi Pharmaceutical Industries, Ltd. | 4-amino(alkyl)cyclohexane-1-carboxamide compound and use thereof |
US5610042A (en) | 1991-10-07 | 1997-03-11 | Ciba-Geigy Corporation | Methods for stable transformation of wheat |
EP1983056A1 (en) | 1992-07-07 | 2008-10-22 | Japan Tobacco Inc. | Method for transforming monocotyledons |
US5702932A (en) | 1992-07-20 | 1997-12-30 | University Of Florida | Microinjection methods to transform arthropods with exogenous DNA |
HUT70467A (en) | 1992-07-27 | 1995-10-30 | Pioneer Hi Bred Int | An improved method of agrobactenium-mediated transformation of cultvred soyhean cells |
DE4228457A1 (en) | 1992-08-27 | 1994-04-28 | Beiersdorf Ag | Production of heterodimeric PDGF-AB using a bicistronic vector system in mammalian cells |
GB9222888D0 (en) | 1992-10-30 | 1992-12-16 | British Tech Group | Tomography |
US5656610A (en) | 1994-06-21 | 1997-08-12 | University Of Southern California | Producing a protein in a mammal by injection of a DNA-sequence into the tongue |
FR2722208B1 (en) | 1994-07-05 | 1996-10-04 | Inst Nat Sante Rech Med | NEW INTERNAL RIBOSOME ENTRY SITE, VECTOR CONTAINING SAME AND THERAPEUTIC USE |
US5736524A (en) | 1994-11-14 | 1998-04-07 | Merck & Co.,. Inc. | Polynucleotide tuberculosis vaccine |
US5843780A (en) | 1995-01-20 | 1998-12-01 | Wisconsin Alumni Research Foundation | Primate embryonic stem cells |
US5728581A (en) | 1995-06-07 | 1998-03-17 | Systemix, Inc. | Method of expanding hematopoietic stem cells, reagents and bioreactors for use therein |
US5780448A (en) | 1995-11-07 | 1998-07-14 | Ottawa Civic Hospital Loeb Research | DNA-based vaccination of fish |
US20030059913A1 (en) | 1995-11-20 | 2003-03-27 | Walter Weyler | Novel Microorganisms with ability to degrade indole and novel enzymes therefrom |
US5928906A (en) | 1996-05-09 | 1999-07-27 | Sequenom, Inc. | Process for direct sequencing during template amplification |
US5945100A (en) | 1996-07-31 | 1999-08-31 | Fbp Corporation | Tumor delivery vehicles |
US5981274A (en) | 1996-09-18 | 1999-11-09 | Tyrrell; D. Lorne J. | Recombinant hepatitis virus vectors |
EP0986635A4 (en) | 1997-01-10 | 2001-11-07 | Life Technologies Inc | Embryonic stem cell serum replacement |
US5994624A (en) | 1997-10-20 | 1999-11-30 | Cotton Incorporated | In planta method for the production of transgenic plants |
AU1197699A (en) | 1997-10-23 | 1999-05-10 | Geron Corporation | Methods and materials for the growth of primate-derived primordial stem cells |
US20030044978A1 (en) | 1998-02-05 | 2003-03-06 | Novartis Corporation | Expanded and genetically modified populations of human hematopoietic stem cells |
US6110929A (en) | 1998-07-28 | 2000-08-29 | 3M Innovative Properties Company | Oxazolo, thiazolo and selenazolo [4,5-c]-quinolin-4-amines and analogs thereof |
US20020168766A1 (en) | 2000-01-11 | 2002-11-14 | Gold Joseph D. | Genetically altered human pluripotent stem cells |
US6667176B1 (en) | 2000-01-11 | 2003-12-23 | Geron Corporation | cDNA libraries reflecting gene expression during growth and differentiation of human pluripotent stem cells |
US6331539B1 (en) | 1999-06-10 | 2001-12-18 | 3M Innovative Properties Company | Sulfonamide and sulfamide substituted imidazoquinolines |
US6541485B1 (en) | 1999-06-10 | 2003-04-01 | 3M Innovative Properties Company | Urea substituted imidazoquinolines |
US6451810B1 (en) | 1999-06-10 | 2002-09-17 | 3M Innovative Properties Company | Amide substituted imidazoquinolines |
EP1231836A4 (en) * | 1999-11-17 | 2004-06-02 | Univ Rochester | Human ex vivo immune system |
WO2001051617A1 (en) * | 2000-01-11 | 2001-07-19 | Maxygen, Inc. | Monocyte-derived dendritic cell subsets |
US6602711B1 (en) | 2000-02-21 | 2003-08-05 | Wisconsin Alumni Research Foundation | Method of making embryoid bodies from primate embryonic stem cells |
EP1302533A4 (en) | 2000-05-16 | 2004-11-17 | Kyowa Hakko Kogyo Kk | Novel method of inducing the differentiation of embryonic stem cells into ectodermal cells and use thereof |
JP5943533B2 (en) | 2000-05-17 | 2016-07-06 | アステリアス バイオセラピューティクス インコーポレイテッド | Neural progenitor cell population |
WO2002044343A2 (en) | 2000-11-22 | 2002-06-06 | Geron Corporation | Tolerizing allografts of pluripotent stem cells |
JP2002184539A (en) | 2000-12-14 | 2002-06-28 | Auto Network Gijutsu Kenkyusho:Kk | Connector |
ES2280517T3 (en) | 2001-03-23 | 2007-09-16 | Bayer Pharmaceuticals Corporation | RHO-CINASA INHIBITOR. |
CA2441492C (en) | 2001-03-23 | 2011-08-09 | Bayer Corporation | Rho-kinase inhibitors |
CA2351156A1 (en) | 2001-07-04 | 2003-01-04 | Peter W. Zandstra | A bioprocess for the generation of pluripotent cell derived cells and tissues |
WO2003006950A2 (en) | 2001-07-12 | 2003-01-23 | Geron Corporation | Cells of the cardiomyocyte lineage produced from human pluripotent stem cells |
US20030211603A1 (en) | 2001-08-14 | 2003-11-13 | Earp David J. | Reprogramming cells for enhanced differentiation capacity using pluripotent stem cells |
JP2003097552A (en) | 2001-09-21 | 2003-04-03 | Nsk Ltd | Friction applying device and linear motion guide |
US20030062225A1 (en) | 2001-10-03 | 2003-04-03 | Stucky Paul A. | Elevator load bearing assembly having a detectable element that is indicative of local strain |
KR20130072272A (en) | 2001-12-07 | 2013-07-01 | 제론 코포레이션 | Hematopoietic cells from human embryonic stem cells |
ES2305435T3 (en) | 2002-01-10 | 2008-11-01 | Bayer Healthcare Ag | INHIBITORS OF RHO-QUINASA. |
MXPA04007191A (en) | 2002-01-23 | 2005-03-31 | Bayer Pharmaceuticals Corp | Pyrimidine derivatives as rho-kinase inhibitors. |
DE60318177T2 (en) | 2002-01-23 | 2008-10-09 | Bayer Pharmaceuticals Corp., West Haven | RHO-KINASE INHIBITORS |
WO2003062404A1 (en) | 2002-01-25 | 2003-07-31 | Gamida-Cell Ltd. | Methods of expanding stem and progenitor cells and expanded cell populations obtained thereby |
WO2004098490A2 (en) | 2002-05-17 | 2004-11-18 | Mount Sinai School Of Medicine Of New York University | Mesoderm and definitive endoderm cell populations |
US20040039796A1 (en) | 2002-08-08 | 2004-02-26 | Virtual Radio, Inc. | Personalized cyber disk jockey and Internet radio advertising |
JP4681451B2 (en) | 2002-10-28 | 2011-05-11 | バイエル・シェーリング・ファルマ・アクチェンゲゼルシャフト | Heteroaryloxy-substituted phenylaminopyrimidines as RHO-kinase inhibitors |
US7986994B2 (en) | 2002-12-04 | 2011-07-26 | Medtronic, Inc. | Method and apparatus for detecting change in intrathoracic electrical impedance |
US7575925B2 (en) * | 2002-12-10 | 2009-08-18 | Sunnybrook Health Sciences Centre | Cell preparations comprising cells of the T cell lineage and methods of making and using them |
US7485432B2 (en) | 2003-02-27 | 2009-02-03 | 3M Innovative Properties Company | Selective modulation of TLR-mediated biological activity |
US20060205071A1 (en) | 2003-07-17 | 2006-09-14 | Gamida-Cell Ltd. | Methods for ex-vivo expanding stem/progenitor cells |
US7795404B1 (en) | 2003-08-08 | 2010-09-14 | Five Prime Therapeutics, Inc. | Human soluble notch receptor ligands |
EP1670900A4 (en) | 2003-08-27 | 2008-06-11 | Stemcells California Inc | Enriched pancreatic stem cell and progenitor cell populations, and methods for identifying, isolating and enriching for such populations |
US20060073591A1 (en) * | 2004-01-09 | 2006-04-06 | Abitorabi M A | Cell culture media |
WO2005080554A1 (en) | 2004-02-23 | 2005-09-01 | Kyoto University | Method of controlling the differentiation of embryonic stem cells |
US7452718B2 (en) | 2004-03-26 | 2008-11-18 | Geron Corporation | Direct differentiation method for making cardiomyocytes from human embryonic stem cells |
EP1783205B1 (en) | 2004-06-18 | 2024-02-21 | Riken | Method of inducing the differentiation of embryonic stem cells into nerve by serum-free suspension culture |
US20080038820A1 (en) | 2004-06-22 | 2008-02-14 | Rudy-Reil Diane E | Induction of pluripotent stem cells into mesodermal lineages |
KR20070058584A (en) | 2004-09-08 | 2007-06-08 | 위스콘신 얼럼나이 리서어치 화운데이션 | Culturing human embryonic stem cells |
JP2008523823A (en) | 2004-12-22 | 2008-07-10 | イーエス・セル・インターナショナル・プライヴェート・リミテッド | Differentiation of human embryonic stem cells and cardiomyocytes and myocardial progenitor cells derived therefrom |
WO2007027226A2 (en) | 2005-04-28 | 2007-03-08 | Board Of Regents, The University Of Texas System | Systems and methods for the production of differentiated cells |
EP2327774A3 (en) | 2005-10-18 | 2011-09-28 | Precision Biosciences | Rationally-designed meganucleases with altered sequence specificity and DNA-binding affinity |
US20070116680A1 (en) | 2005-11-18 | 2007-05-24 | Rensselaer Polytechnic Institute | Stem cells within gel microenvironments |
EP1815863A1 (en) | 2006-02-03 | 2007-08-08 | Nederlandse Organisatie voor toegepast-natuurwetenschappelijk Onderzoek TNO | Use of TLR3 agonists for the treatment of neurodegenerative disorders |
GB2436737B (en) | 2006-03-30 | 2008-07-09 | Univ Edinburgh | Culture medium containing kinase inhibitors,and uses thereof |
WO2008005268A1 (en) | 2006-06-30 | 2008-01-10 | Schering Corporation | Substituted piperidines that increase p53 activity and the uses thereof |
MX2009000310A (en) | 2006-07-14 | 2009-01-26 | Novartis Ag | Pyrimidine derivatives as alk-5 inhibitors. |
SE0950586L (en) | 2007-01-17 | 2009-08-13 | Wisconsin Alumni Res Found | Improved culture of stem cells |
US9175260B2 (en) | 2007-01-30 | 2015-11-03 | TheUniversity of Georgia Research Foundation, Inc. | Early mesoderm cells, a stable population of mesendoderm cells that has utility for generation of endoderm and mesoderm lineages and multipotent migratory cells (MMC) |
US8377886B2 (en) | 2007-09-14 | 2013-02-19 | Albert Einstein College Of Medicine Of Yeshiva University | Use of gamma secretase inhibitors and notch pathway inhibitors for treatment and prevention of renal disease |
US10059923B2 (en) * | 2008-01-30 | 2018-08-28 | Memorial Sloan Kettering Cancer Center | Methods for off-the-shelf tumor immunotherapy using allogeneic T-cell precursors |
US10350243B2 (en) * | 2008-01-30 | 2019-07-16 | Memorial Sloan-Kettering Cancer Center | Methods for off-the-shelf-tumor immunotherapy using allogeneic T-cell precursors |
ES2622505T3 (en) * | 2008-05-09 | 2017-07-06 | Agency For Science, Technology And Research | Exogenous T lymphocyte receptor (RLT) reactive against HBV epitope and uses thereof |
DE102008040322A1 (en) | 2008-07-10 | 2010-09-16 | Dilo Trading Ag | Energy storage circulatory system using lithium-ion cells |
CA2736851A1 (en) * | 2008-09-11 | 2010-03-18 | Lung-Ji Chang | System and method for producing t cells |
PE20100362A1 (en) | 2008-10-30 | 2010-05-27 | Irm Llc | PURINE DERIVATIVES THAT EXPAND HEMATOPOYETIC STEM CELLS |
CA2743669C (en) | 2008-11-24 | 2018-10-16 | Helmholtz Zentrum Muenchen Deutsches Forschungszentrum Fuer Gesundheit Und Umwelt (Gmbh) | High affinity t cell receptor and use thereof |
KR101720961B1 (en) | 2009-02-27 | 2017-03-29 | 셀룰러 다이내믹스 인터내셔널, 인코포레이티드 | Differentiation of pluripotent cells |
EP2539441B1 (en) | 2010-02-22 | 2016-09-28 | Université Pierre et Marie Curie (Paris 6) | Cell culture medium for the growth and differentiation of cells of the hematopoietic lineage |
GB201006768D0 (en) | 2010-04-22 | 2010-06-09 | Cancer Rec Tech Ltd | Method for obtaining dendritic cells |
ES2620748T3 (en) | 2010-06-25 | 2017-06-29 | Idera Pharmaceuticals, Inc. | New toll 3 receptor agonists and procedures for their use |
WO2014039044A1 (en) * | 2012-09-06 | 2014-03-13 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Methods of producing t memory stem cell populations |
EP2906684B8 (en) | 2012-10-10 | 2020-09-02 | Sangamo Therapeutics, Inc. | T cell modifying compounds and uses thereof |
US20160017302A1 (en) * | 2013-03-05 | 2016-01-21 | Baylor College Of Medicine | Heparanase expression in human t lymphocytes |
US9409760B1 (en) | 2013-12-05 | 2016-08-09 | Paul Lichtefeld, Sr. | Fluid dispenser |
US9410501B2 (en) | 2014-04-25 | 2016-08-09 | Rohr, Inc. | Translating sleeve actuation system and apparatus |
EP3298131B1 (en) | 2015-05-20 | 2023-04-26 | The Regents of The University of California | Method for generating human dendritic cells for immunotherapy |
MX2018005274A (en) | 2015-10-30 | 2019-09-19 | The Regents Of The Universtiy Of California | Methods of generating t-cells from stem cells and immunotherapeutic methods using the t-cells. |
-
2016
- 2016-10-28 MX MX2018005274A patent/MX2018005274A/en unknown
- 2016-10-28 CN CN201680077607.7A patent/CN108463548B/en active Active
- 2016-10-28 AU AU2016343682A patent/AU2016343682A1/en not_active Abandoned
- 2016-10-28 EP EP16860902.2A patent/EP3368660A4/en active Pending
- 2016-10-28 KR KR1020187015441A patent/KR20180092951A/en not_active Application Discontinuation
- 2016-10-28 IL IL258899A patent/IL258899B2/en unknown
- 2016-10-28 TW TW105135186A patent/TWI812584B/en active
- 2016-10-28 JP JP2018522655A patent/JP6983771B2/en active Active
- 2016-10-28 BR BR112018008648A patent/BR112018008648A2/en active Search and Examination
- 2016-10-28 US US15/772,224 patent/US11154573B2/en active Active
- 2016-10-28 WO PCT/US2016/059375 patent/WO2017075389A1/en active Application Filing
- 2016-10-28 CA CA3003145A patent/CA3003145A1/en active Pending
- 2016-10-28 SG SG11201803419PA patent/SG11201803419PA/en unknown
- 2016-10-28 TW TW112127839A patent/TW202344686A/en unknown
-
2021
- 2021-09-17 US US17/478,875 patent/US20220096553A1/en active Pending
- 2021-11-24 JP JP2021189828A patent/JP7402211B2/en active Active
-
2023
- 2023-04-11 AU AU2023202195A patent/AU2023202195A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
TW201730334A (en) | 2017-09-01 |
BR112018008648A2 (en) | 2018-11-27 |
WO2017075389A1 (en) | 2017-05-04 |
JP6983771B2 (en) | 2021-12-17 |
US20220096553A1 (en) | 2022-03-31 |
AU2016343682A1 (en) | 2018-06-14 |
CN108463548B (en) | 2023-04-18 |
IL258899B2 (en) | 2024-03-01 |
TW202344686A (en) | 2023-11-16 |
AU2023202195A1 (en) | 2023-05-11 |
KR20180092951A (en) | 2018-08-20 |
CA3003145A1 (en) | 2017-05-04 |
IL258899B1 (en) | 2023-11-01 |
TWI812584B (en) | 2023-08-21 |
JP2022033812A (en) | 2022-03-02 |
JP7402211B2 (en) | 2023-12-20 |
WO2017075389A8 (en) | 2018-05-24 |
US11154573B2 (en) | 2021-10-26 |
US20190231817A1 (en) | 2019-08-01 |
MX2018005274A (en) | 2019-09-19 |
CN108463548A (en) | 2018-08-28 |
EP3368660A1 (en) | 2018-09-05 |
NZ742915A (en) | 2024-02-23 |
JP2018533364A (en) | 2018-11-15 |
IL258899A (en) | 2018-06-28 |
EP3368660A4 (en) | 2019-04-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL258899A (en) | Methods of generating t-cells from stem cells and immunotherapeutic methods using the t-cells | |
HK1250481A1 (en) | Modified t cells and methods of making and using the same | |
HRP20192145T1 (en) | Carrier-antibody compositions and methods of making and using the same | |
HK1244841A1 (en) | Methods and compositions for selectively eliminating cells of interest | |
HK1232239A1 (en) | Cell penetrating peptides and methods of making and using thereof | |
HK1246342A1 (en) | METHODS FOR GENERATING STEM CELL-DERIVED ß CELLS AND USES THEREOF | |
IL263743A (en) | Compositions and methods for the depletion of cells | |
IL251576A0 (en) | Methods and compositions for generating or maintaining pluripotent cells | |
HK1232140A1 (en) | Micro-organoids, and methods of making and using the same | |
IL297238B2 (en) | Methods and compositions for the activation of gamma-delta t-cells | |
IL263611B (en) | Pd-l1-specific antibodies and methods of using the same | |
IL269334A (en) | Improved t cell compositions and methods | |
GB201709599D0 (en) | Methods for generation of podocytes from pluripotent stem cells and cells produced by the same | |
GB201712733D0 (en) | Methods & cells | |
GB201519128D0 (en) | Solid forms and methods of preparing the same | |
EP3383182C0 (en) | Methods for generating functional hematopoietic stem cells | |
PL3586821T3 (en) | Stem cell stimulating compositions and methods | |
EP3307873A4 (en) | Hematopoietic cells and methods of using and generating the same | |
PT3113774T (en) | Compositions of grapiprant and methods for using the same | |
GB201706498D0 (en) | Mechanically strengthened bond between thermally stable polycrystalline hard materials and hard components | |
GB201518637D0 (en) | Cell co-cultures and methods of making the same |